Advertisement

Research Article Free access | 10.1172/JCI108106

Effect of osteoclast activating factor from human leukocytes on bone metabolism.

L G Raisz, R A Luben, G R Mundy, J W Dietrich, J E Horton, and C L Trummel

Find articles by Raisz, L. in: JCI | PubMed | Google Scholar

Find articles by Luben, R. in: JCI | PubMed | Google Scholar

Find articles by Mundy, G. in: JCI | PubMed | Google Scholar

Find articles by Dietrich, J. in: JCI | PubMed | Google Scholar

Find articles by Horton, J. in: JCI | PubMed | Google Scholar

Find articles by Trummel, C. in: JCI | PubMed | Google Scholar

Published August 1, 1975 - More info

Published in Volume 56, Issue 2 on August 1, 1975
J Clin Invest. 1975;56(2):408–413. https://doi.org/10.1172/JCI108106.
© 1975 The American Society for Clinical Investigation
Published August 1, 1975 - Version history
View PDF
Abstract

The effects of osteoclast activating factor (OAF) released by normal human peripheral blood leukocytes cultured with phytohemagglutinin have been examined in organ culture. Like parathyroid hormone (PTH), OAF causes a rapid increased in the release of previously incorporated 45Ca from fetal rat bone after brief or continuous exposure; the bones also lose stable calcium and collagen content. The resorption response to OAF also resembles that of PTH in having a steep dose response curve and being only transiently inhibited by calcitonin and partially inhibited by increasing medium phosphate concentration. OAF-stimulated resorption was inhibited more effectively by cortisol than was PTH stimulation. The response to maximally effective doses of OAF was not enhanced by PTH or prostaglandin E2, but submaximal doses gave additive effects. Both OAF and PTH inhibit collagen synthesis in fetal rat calvaria at the concentrations that stimulate bone resorption.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (August 1, 1975): No description
Advertisement
Advertisement